FDA Approved New Pancreatic Cancer Drug Daraxonrasib
The oral therapy has been shown to double median survival time for patients with metastatic pancreatic cancer.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Do you trust that new medical breakthroughs will be accessible to you when you need them?
The FDA has officially approved daraxonrasib, an oral medication designed to treat pancreatic cancer by targeting KRAS mutations. Clinical trials demonstrated that the drug effectively doubles the median survival time for patients suffering from the metastatic form of the disease.
Why it matters
Pancreatic cancer currently ranks as the third leading cause of cancer deaths in the United States and historically suffers from limited treatment options. Providing a new therapy for the 90% of cases involving KRAS mutations offers a critical lifeline for patients who often receive a diagnosis in the late stages.
Clinical data showed a median survival increase to 13.2 months from a baseline of 6.7 months among the 500 trial participants. The treatment targets KRAS mutations, which are present in 90% of the 67,000 Americans diagnosed with the disease annually.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Intermountain Health
This is a regional non-profit healthcare system that operates numerous hospitals across several western states.
American Society of Clinical Oncology
This is a professional organization representing oncology physicians and researchers that hosts an annual conference to discuss cancer care.
The details
Daraxonrasib functions as an oral therapy that inhibits signaling pathways, effectively shutting down the growth of cancer cells. Ten Intermountain Health hospitals across Utah, Colorado, and Montana previously participated in an Expanded Access Protocol to provide the treatment to patients during the testing phase.
Timeline
May 2026: Clinical trial results were presented at the ASCO conference.
September 22, 2026: The drug approval was formally announced.
Health Landscape
The presentation of these findings at the American Society of Clinical Oncology conference mirrors the standard trajectory for oncological breakthroughs. This approval highlights the shift toward targeted molecular therapies in oncology, moving away from broader, less specific treatment methods.
Patients with metastatic pancreatic cancer may now have access to a daily oral therapy that extends median survival time significantly. Individuals should consult their oncologists to determine if their specific KRAS-mutation profile qualifies them for the new prescription treatment.
The takeaway
This approval introduces a significant new therapeutic option for one of the deadliest forms of cancer. Patients and their families are encouraged to monitor updates on insurance coverage as health plans finalize formulary inclusion for the medication.
Further reading
Learn more about the latest developments in oncological care and research in the Cancer section.
Live Poll
Do you trust that new medical breakthroughs will be accessible to you when you need them?
